The DOI matches its Crossref record, with a small difference in title or year; 34 of the 34 references it cites were found in a registry or an index; 15 of the 25 sources its claims cite were checked for support.
The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling
Open accessAbstract
FKBP52 and β-catenin have emerged in recent years as attractive targets for prostate cancer treatment. β-catenin interacts directly with the androgen receptor (AR) and has been characterized as a co-activator of AR-mediated transcription. FKBP52 is a positive regulator of AR in cellular and whole animal models and is required for the development of androgen-dependent tissues. We previously characterized an AR inhibitor termed MJC13 that putatively targets the AR BF3 surface to specifically inhibit FKBP52-regulated AR signaling. Predictive modeling suggests that β-catenin interacts with the AR hormone binding domain on a surface that overlaps with BF3. Here we demonstrate that FKBP52 and β-catenin interact directly in vitro and act in concert to promote a synergistic up-regulation of both hormone-independent and -dependent AR signaling. Our data demonstrate that FKBP52 promotes β-catenin interaction with AR and is required for β-catenin co-activation of AR activity in prostate cancer cells. MJC13 effectively blocks β-catenin interaction with the AR LBD and the synergistic up-regulation of AR by FKBP52 and β-catenin. Our data suggest that co-regulation of AR by FKBP52 and β-catenin does not require FKBP52 PPIase catalytic activity, nor FKBP52 binding to Hsp90. However, the FKBP52 proline-rich loop that overhangs the PPIase pocket is critical for synergy.
Overview
CoChat Summary
## TL;DR
FKBP52 and β-catenin directly cooperate to enhance androgen receptor (AR) signaling, and FKBP52 is required for β-catenin’s co-activation of AR in the systems tested. The AR inhibitor MJC13 blocked the β-catenin–AR interaction and abolished the synergistic AR activation driven by FKBP52 plus β-catenin.
## Key findings
- In a cell-free GST pull-down assay, recombinant FKBP52 directly co-precipitated with GST-tagged β-catenin, showing a direct FKBP52–β-catenin interaction in vitro.
- In 52KO mouse embryonic fibroblasts, co-expression of FKBP52 with β-catenin or β-catenin S33A produced synergistic AR reporter activation: 17-fold and 25-fold enhancement of hormone-dependent AR activity, respectively, and 10-fold enhancement of hormone-independent activity.
- In HeLa cells, co-expression of FKBP52 and β-catenin S33Y increased Gal4-AR LBD activity 9-fold; FKBP52 knockdown reduced β-catenin-driven AR LBD activity by 2-fold and 4-fold in the conditions described.
- In 22Rv1 prostate cancer cells, β-catenin S33A potentiated AR-mediated luciferase expression up to 3-fold in wild-type cells, but this effect was lost or not statistically significant after FKBP52 knockdown; MJC13 completely inhibited both hormone-independent and hormone-dependent AR activity mediated by FKBP52 and β-catenin at low micromolar concentrations.
## Methods
- The study used multiple cell systems: 52KO MEF, HeLa, 293T, LNCaP, and 22Rv1 cells, plus recombinant proteins for in vitro binding assays.
- Main assays included GST pull-down, co-immunoprecipitation, mammalian two-hybrid, and luciferase reporter assays to test FKBP52–β-catenin interaction and effects on AR signaling.
- Functional tests included FKBP52 overexpression, siRNA/shRNA knockdown, AR and β-catenin mutant constructs, DHT stimulation, and treatment with MJC13.
## Limitations
- The paper states that the hormone-independent effects were inconsistent between assays, so no firm conclusions could be drawn about that component.
- The authors note that stable FKBP52 knockdown could not be achieved in LNCaP and PC3 cells, limiting prostate-cancer-cell testing to 22Rv1 cells; this is stated in the paper.
- Evident from the text: several conclusions rely on overexpression and reporter assays, which may not fully capture endogenous AR signaling context.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
13 Valid · 1 Not valid · 9 Not checked · 86 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Given that these residues reside within the proline-rich loop, these studies highlighted the importance of the proline-rich loop for potentiation of receptor activity.”
§ The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling > Results > FKBP52 domain requirements for β-catenin co-regulation of AR Given that FKBP52 can potentiate AR activity through interaction with Hsp90, and in the absence of β-catenin in yeast, we aimed to determine if the pre-established domain and functional requirements for FKBP52 potentiation of AR activity alone directly mirror those of FKBP52 co-regulation with β-catenin. While both Hsp90 binding and the FKBP52 proline-rich loop are known to be critical, FKBP52 PPIase catalytic activity is not required [7, 12]. We took advantage of the FKBP52 mutants generated previously, including PPIase-deficient, Hsp90-binding deficient, and proline-rich loop mutants, to characterize the FKBP52 domain requirements for co-regulation with β-catenin using AR-mediated luciferase assays in 52KO MEF cells (Fig 5). The FKBP52 mutation F130Y abrogates PPIase activity without disrupting the conformation of the proline-rich loop, and without inhibiting FKBP52 potentiation of AR activity alone [12]. We assessed FKBP52 (F130Y) for the ability to co-regulate AR activity with β-catenin. The co-expression of FKBP52 (F130Y) with β-catenin (S33A) resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression comparable to that observed with wild type FKBP52 both in the absence and presence of hormone (Fig 5A). Both wild type FKBP52 and FKBP52 (F130Y) overexpression resulted in a 9-fold enhancement of receptor-mediated reporter expression as compared to the vector control in the absence of hormone. Thus, the PPIase-deficient mutant can also support hormone-independent receptor activity. In addition, wild type FKBP52 and FKBP52 (F130Y) overexpression resulted in a 22-fold and 27-fold enhancement of hormone-dependent, receptor-mediated reporter expression respectively. These data are strikingly similar to those reported in Fig 3A. The co-expression of FKBP52 (K354A), which completely lacks Hsp90 binding [7], with β-catenin (S33A) also resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression comparable to that observed with wild type FKBP52 both in the presence and absence of hormone (Fig 5B). In this assay, FKBP52 (K354A) overexpression was able to enhance hormone-independent receptor activity up to 7-fold in addition to enhancing hormone-dependent activity up to 15-fold. It is important to note that in this assay wild type FKBP52 overexpression did enhance hormone-independent receptor activity, but the increase was not statistically significant as compared to vector alone. This reflects the fact that, while a trend for increased hormone-independent activity is present in all assays, this effect is not always consistently significant. In contrast to that observed with FKBP52 alone, these data suggest that both PPIase catalytic activity and FKBP52 binding to Hsp90 are not required for the synergistic up-regulation of both hormone-independent and hormone-dependent AR activity by FKBP52 and β-catenin. Previous studies demonstrated that two mutations (A116V/L119P) in FKBP51, which does not potentiate AR activity alone, conferred the ability to fully potentiate receptor activity similar to that of FKBP52 [12]. Given that these residues reside within the proline-rich loop, these studies highlighted the importance of the proline-rich loop for potentiation of receptor activity. Interestingly, while FKBP51 lacked the ability to co-regulate with β-catenin (S33A), the co-expression of FKBP51 (A116V/L119P) with β-catenin (S33A) resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression in the presence of hormone (10-fold enhancement as compared to vector alone) (Fig 5C). These data suggest that the FKBP52 proline-rich loop is critical for co-regulation of AR activity with β-catenin. While FKBP51 (A116V/L119P) was capable of synergizing with β-catenin to promote hormone-dependent receptor activity, we observed no statistically significant enhancements of hormone-independent receptor activity, nor a trend for enhancement in the presence of FKBP51 (A116V/L119P). These data may suggest that functional residues and domains on FKBP52 other than the proline-rich loop may contribute to FKBP52/β-catenin potentiation of hormone-independent receptor activity. However, we are cautious in making such a conclusion given that the hormone-independent effects lack consistency.
What the sources say
- Supportedcites [12] DL Riggs, 2007, Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling, Mol Cell Biol source
The Results identify A116V and L119P among mutations at residues in the same loop over the PPIase pocket. The Discussion explicitly links mutations at positions 116 and 119 in that loop to potentiation of receptor activity. The paper calls it the PPIase loop rather than the “proline-rich loop.” (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The co-expression of FKBP52 (K354A), which completely lacks Hsp90 binding [7], with β-catenin (S33A) also resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression comparable to that observed with wild type FKBP52 both in the presence and absence of hormone (Fig 5B).”
§ The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling > Results > FKBP52 domain requirements for β-catenin co-regulation of AR Given that FKBP52 can potentiate AR activity through interaction with Hsp90, and in the absence of β-catenin in yeast, we aimed to determine if the pre-established domain and functional requirements for FKBP52 potentiation of AR activity alone directly mirror those of FKBP52 co-regulation with β-catenin. While both Hsp90 binding and the FKBP52 proline-rich loop are known to be critical, FKBP52 PPIase catalytic activity is not required [7, 12]. We took advantage of the FKBP52 mutants generated previously, including PPIase-deficient, Hsp90-binding deficient, and proline-rich loop mutants, to characterize the FKBP52 domain requirements for co-regulation with β-catenin using AR-mediated luciferase assays in 52KO MEF cells (Fig 5). The FKBP52 mutation F130Y abrogates PPIase activity without disrupting the conformation of the proline-rich loop, and without inhibiting FKBP52 potentiation of AR activity alone [12]. We assessed FKBP52 (F130Y) for the ability to co-regulate AR activity with β-catenin. The co-expression of FKBP52 (F130Y) with β-catenin (S33A) resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression comparable to that observed with wild type FKBP52 both in the absence and presence of hormone (Fig 5A). Both wild type FKBP52 and FKBP52 (F130Y) overexpression resulted in a 9-fold enhancement of receptor-mediated reporter expression as compared to the vector control in the absence of hormone. Thus, the PPIase-deficient mutant can also support hormone-independent receptor activity. In addition, wild type FKBP52 and FKBP52 (F130Y) overexpression resulted in a 22-fold and 27-fold enhancement of hormone-dependent, receptor-mediated reporter expression respectively. These data are strikingly similar to those reported in Fig 3A. The co-expression of FKBP52 (K354A), which completely lacks Hsp90 binding [7], with β-catenin (S33A) also resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression comparable to that observed with wild type FKBP52 both in the presence and absence of hormone (Fig 5B). In this assay, FKBP52 (K354A) overexpression was able to enhance hormone-independent receptor activity up to 7-fold in addition to enhancing hormone-dependent activity up to 15-fold. It is important to note that in this assay wild type FKBP52 overexpression did enhance hormone-independent receptor activity, but the increase was not statistically significant as compared to vector alone. This reflects the fact that, while a trend for increased hormone-independent activity is present in all assays, this effect is not always consistently significant. In contrast to that observed with FKBP52 alone, these data suggest that both PPIase catalytic activity and FKBP52 binding to Hsp90 are not required for the synergistic up-regulation of both hormone-independent and hormone-dependent AR activity by FKBP52 and β-catenin. Previous studies demonstrated that two mutations (A116V/L119P) in FKBP51, which does not potentiate AR activity alone, conferred the ability to fully potentiate receptor activity similar to that of FKBP52 [12]. Given that these residues reside within the proline-rich loop, these studies highlighted the importance of the proline-rich loop for potentiation of receptor activity. Interestingly, while FKBP51 lacked the ability to co-regulate with β-catenin (S33A), the co-expression of FKBP51 (A116V/L119P) with β-catenin (S33A) resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression in the presence of hormone (10-fold enhancement as compared to vector alone) (Fig 5C). These data suggest that the FKBP52 proline-rich loop is critical for co-regulation of AR activity with β-catenin. While FKBP51 (A116V/L119P) was capable of synergizing with β-catenin to promote hormone-dependent receptor activity, we observed no statistically significant enhancements of hormone-independent receptor activity, nor a trend for enhancement in the presence of FKBP51 (A116V/L119P). These data may suggest that functional residues and domains on FKBP52 other than the proline-rich loop may contribute to FKBP52/β-catenin potentiation of hormone-independent receptor activity. However, we are cautious in making such a conclusion given that the hormone-independent effects lack consistency.
What the sources say
- Supportedcites [7] DL Riggs, 2003, The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo, EMBO J source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previous studies demonstrated that two mutations (A116V/L119P) in FKBP51, which does not potentiate AR activity alone, conferred the ability to fully potentiate receptor activity similar to that of FKBP52 [12].”
§ The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling > Results > FKBP52 domain requirements for β-catenin co-regulation of AR Given that FKBP52 can potentiate AR activity through interaction with Hsp90, and in the absence of β-catenin in yeast, we aimed to determine if the pre-established domain and functional requirements for FKBP52 potentiation of AR activity alone directly mirror those of FKBP52 co-regulation with β-catenin. While both Hsp90 binding and the FKBP52 proline-rich loop are known to be critical, FKBP52 PPIase catalytic activity is not required [7, 12]. We took advantage of the FKBP52 mutants generated previously, including PPIase-deficient, Hsp90-binding deficient, and proline-rich loop mutants, to characterize the FKBP52 domain requirements for co-regulation with β-catenin using AR-mediated luciferase assays in 52KO MEF cells (Fig 5). The FKBP52 mutation F130Y abrogates PPIase activity without disrupting the conformation of the proline-rich loop, and without inhibiting FKBP52 potentiation of AR activity alone [12]. We assessed FKBP52 (F130Y) for the ability to co-regulate AR activity with β-catenin. The co-expression of FKBP52 (F130Y) with β-catenin (S33A) resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression comparable to that observed with wild type FKBP52 both in the absence and presence of hormone (Fig 5A). Both wild type FKBP52 and FKBP52 (F130Y) overexpression resulted in a 9-fold enhancement of receptor-mediated reporter expression as compared to the vector control in the absence of hormone. Thus, the PPIase-deficient mutant can also support hormone-independent receptor activity. In addition, wild type FKBP52 and FKBP52 (F130Y) overexpression resulted in a 22-fold and 27-fold enhancement of hormone-dependent, receptor-mediated reporter expression respectively. These data are strikingly similar to those reported in Fig 3A. The co-expression of FKBP52 (K354A), which completely lacks Hsp90 binding [7], with β-catenin (S33A) also resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression comparable to that observed with wild type FKBP52 both in the presence and absence of hormone (Fig 5B). In this assay, FKBP52 (K354A) overexpression was able to enhance hormone-independent receptor activity up to 7-fold in addition to enhancing hormone-dependent activity up to 15-fold. It is important to note that in this assay wild type FKBP52 overexpression did enhance hormone-independent receptor activity, but the increase was not statistically significant as compared to vector alone. This reflects the fact that, while a trend for increased hormone-independent activity is present in all assays, this effect is not always consistently significant. In contrast to that observed with FKBP52 alone, these data suggest that both PPIase catalytic activity and FKBP52 binding to Hsp90 are not required for the synergistic up-regulation of both hormone-independent and hormone-dependent AR activity by FKBP52 and β-catenin. Previous studies demonstrated that two mutations (A116V/L119P) in FKBP51, which does not potentiate AR activity alone, conferred the ability to fully potentiate receptor activity similar to that of FKBP52 [12]. Given that these residues reside within the proline-rich loop, these studies highlighted the importance of the proline-rich loop for potentiation of receptor activity. Interestingly, while FKBP51 lacked the ability to co-regulate with β-catenin (S33A), the co-expression of FKBP51 (A116V/L119P) with β-catenin (S33A) resulted in the synergistic up-regulation of AR-mediated luciferase reporter expression in the presence of hormone (10-fold enhancement as compared to vector alone) (Fig 5C). These data suggest that the FKBP52 proline-rich loop is critical for co-regulation of AR activity with β-catenin. While FKBP51 (A116V/L119P) was capable of synergizing with β-catenin to promote hormone-dependent receptor activity, we observed no statistically significant enhancements of hormone-independent receptor activity, nor a trend for enhancement in the presence of FKBP51 (A116V/L119P). These data may suggest that functional residues and domains on FKBP52 other than the proline-rich loop may contribute to FKBP52/β-catenin potentiation of hormone-independent receptor activity. However, we are cautious in making such a conclusion given that the hormone-independent effects lack consistency.
What the sources say
- Supportedcites [12] DL Riggs, 2007, Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling, Mol Cell Biol source
The Results report that wild-type FKBP51 had a minimal effect on AR signaling, while the A116V/L119P double mutant potentiated receptor activity fully equivalently to FKBP52. The Discussion likewise says that adding A116V to FKBP51-L119P raised potentiation to the level observed with wild-type FKBP52. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predictive modeling suggests that β-catenin interacts with the AR hormone binding domain on a surface that overlaps with BF3.”
- Also stated in: § The predicted β-catenin interaction site overlaps with AR BF3 Previous studies demonstrated that β-catenin interacts directly with AR to potentiate receptor activity. While the AR ligand binding domain (LBD) and N-terminus were shown to be important for this functional interaction in yeast [20], mammalian two-hybrid studies suggested that β-catenin binds to the AR AF2 to modulate the effects of the N-terminus on ligand-dependent activity [18]. The recently solved co-crystal structure of the liver receptor homolog-1 (LRH-1) hinge-LBD bound to β-catenin demonstrated that LRH-1 and AR bind to a similar surface on β-catenin [25]. Given the high degree of structural similarity in the LBD among members of the nuclear receptor superfamily, it is also likely that LRH-1 and AR share a similar β-catenin interaction surface. Fig 1A illustrates the three-dimensional structure of the complex of LRH-1 LBD bound to β-catenin that was used for modeling the structure of AR LBD with β-catenin. In Fig 1B the crystal structure of the AR LBD is overlaid onto the LRH-1 LBD by superposition of the common Cα atoms. Super positions of atomic coordinates and molecular drawings were done using Swiss-Pdb Viewer [26]. This model predicts that β-catenin interacts with an AR surface that is near the characterized BF3 surface. This surface is highlighted by the presence of flufenamic acid, a known BF3 binding molecule. In this predictive model for AR interaction with β-catenin, flufenamic acid is within 8 Å of β-catenin. Based on this model, we predict that β-catenin interacts with an AR surface that overlaps with the recently characterized BF3 surface [24], which also represents the putative MJC13 binding site on the AR-FKBP52 complex [13]. · hedged
“This model predicts that β-catenin interacts with an AR surface that is near the characterized BF3 surface.”
§ The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling > Abstract
What the sources say
- Partly supportedcites [25] F Yumoto, 2012, Structural basis of coactivation of liver receptor homolog-1 by beta-catenin, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report that β-catenin interacts with the AR ligand-binding domain, and the Discussion links AR binding to a region of β-catenin also used by LRH-1. Neither section reports predictive modeling that places the contact on an AR surface overlapping BF3; the Discussion says the AR binding interface remains uncertain. The indexed passages provide no page numbers. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § The predicted β-catenin interaction site overlaps with AR BF3 Previous studies demonstrated that β-catenin interacts directly with AR to potentiate receptor activity. While the AR ligand binding domain (LBD) and N-terminus were shown to be important for this functional interaction in yeast [20], mammalian two-hybrid studies suggested that β-catenin binds to the AR AF2 to modulate the effects of the N-terminus on ligand-dependent activity [18]. The recently solved co-crystal structure of the liver receptor homolog-1 (LRH-1) hinge-LBD bound to β-catenin demonstrated that LRH-1 and AR bind to a similar surface on β-catenin [25]. Given the high degree of structural similarity in the LBD among members of the nuclear receptor superfamily, it is also likely that LRH-1 and AR share a similar β-catenin interaction surface. Fig 1A illustrates the three-dimensional structure of the complex of LRH-1 LBD bound to β-catenin that was used for modeling the structure of AR LBD with β-catenin. In Fig 1B the crystal structure of the AR LBD is overlaid onto the LRH-1 LBD by superposition of the common Cα atoms. Super positions of atomic coordinates and molecular drawings were done using Swiss-Pdb Viewer [26]. This model predicts that β-catenin interacts with an AR surface that is near the characterized BF3 surface. This surface is highlighted by the presence of flufenamic acid, a known BF3 binding molecule. In this predictive model for AR interaction with β-catenin, flufenamic acid is within 8 Å of β-catenin. Based on this model, we predict that β-catenin interacts with an AR surface that overlaps with the recently characterized BF3 surface [24], which also represents the putative MJC13 binding site on the AR-FKBP52 complex [13]. · hedged
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because FKBP52 is overexpressed in prostate cancer patients [27], it is feasible that overexpression of FKBP52 could be the cause of increased AR co-activation by β-catenin in prostate cancer.”
§ The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling > Discussion
What the sources say
- Supportedcites [27] JF Lin, 2007, Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis, Int J Cancer source
The Discussion states that FKBP4, also known as FKBP52, was up-regulated in prostate cancer. The paper also describes differential expression in prostate cancer versus control biopsy specimens. The citing sentence presents the proposed effect on β-catenin co-activation as its own inference, not as a finding attributed to this source. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
74 more claims · 1 with their cited sources checked
Create a free account to see all 109 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 16
Citations
Cites
Guex, N., Peitsch, M. C., & Schwede, T. (2009) · ELECTROPHORESIS · doi:10.1002/elps.200900140 · Cited by 2,097
Interaction of Nuclear Receptors with the Wnt/β-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Mulholland, D. J., Dedhar, S., Coetzee, G. A., & Nelson, C. C. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0034 · Cited by 377
The Hsp90‐binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo
Riggs, D. L., Roberts, P. J., Chirillo, S. C., Cheung‐Flynn, J., Prapapanich, V., Ratajczak, T., Gaber, R., Picard, D., & Smith, D. F. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg108 · Cited by 353
Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.
Truica, C. I., Byers, S. W., & Gelmann, E. P. (2000) · PubMed · Cited by 350
Linking β-Catenin to Androgen-signaling Pathway
Yang, F., Li, X., Sharma, M., Sasaki, C. Y., Longo, D. L., Lim, B., & Sun, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111962200 · Cited by 342
A surface on the androgen receptor that allosterically regulates coactivator binding
Estébanez-Perpiñá, E., Arnold, L. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J. D., Guy, R. K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708036104 · Cited by 307 · cited 3×
“In addition, mammalian two-hybrid studies suggested that β-catenin interacts with AR activation function 2 (AF2) [18], a site that is affected allosterically by small molecule binding at the AR BF3 surface [24].”
BackgroundSelf-citationFKBP51 and FKBP52 in signaling and disease
Storer, C. L., Dickey, C. A., Galigniana, M. D., Rein, T., & Cox, M. B. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.08.001 · Cited by 266 · cited 1×
“The regulation of AR activity by the FKBP52 cochaperone alone has been extensively studied and much has been learned about the FKBP52 domain and residue requirements for function (reviewed in [30]).”
BackgroundSelf-citationCochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation
Tranguch, S., Cheung-Flynn, J., Daikoku, T., Prapapanich, V., Cox, M. B., Xie, H., Wang, H., Das, S. K., Smith, D. F., & Dey, S. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505775102 · Cited by 232 · cited 1×
“The fkbp52-deficient mouse embryonic fibroblasts (52KOMEF) were previously described [8].”
Self-citationAcetylation of β-Catenin by p300 Regulates β-Catenin-Tcf4 Interaction
Lévy, L., Wei, Y., Labalette, C., Wu, Y., Renard, C.-A., Buendia, M. A., & Neuveut, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3404-3414.2004 · Cited by 220
Physiological role for the cochaperone FKBP52 in androgen receptor signaling
Cheung-Flynn, J., Prapapanich, V., Cox, M. B., Riggs, D. L., Suarez-Quian, C., & Smith, D. F. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0071 · Cited by 212 · cited 2×
“In agreement with the biochemical and cellular data, FKBP52 is required for normal male reproductive development and success as fkbp52-deficient mice display characteristics of partial androgen insensitivity syndrome including dysgenic prostate [6, 11].”
MethodResult
Cited by
FKBP Ligands—Where We Are and Where to Go?
Kolos, J. M., Voll, A. M., Bauder, M., & Hausch, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01425 · Cited by 158
“This hormone receptor activity makes FKBP52 an interesting target in hormone-driven tumors like prostate cancer, colorectal adenocarcinomas, breast cancer, and myelomas (Storer et al., 2011; Storer Samaniego et al., 2015).”
BackgroundDiverse structures, functions and uses of FK506 binding proteins
Bonner, J. M., & Boulianne, G. L. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.06.013 · Cited by 81
Regulation of masculinization: androgen signalling for external genitalia development
Matsushita, S., Suzuki, K., Murashima, A., Kajioka, D., Acebedo, A. R., Miyagawa, S., Haraguchi, R., Ogino, Y., & Yamada, G. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0008-y · Cited by 76
Federer‐Gsponer, J. R., Quintavalle, C., Müller, D. C., Dietsche, T., Perrina, V., Lorber, T., Juškevičius, D., Lenkiewicz, E., Zellweger, T., Gasser, T., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5052 · Cited by 24
“Recently, it has been reported that the interaction of beta-catenin with FKBP4 potentiates hormone-dependent, as well as hormone-independent, AR activity [53].”
BackgroundEvidence for Hsp90 Co-chaperones in Regulating Hsp90 Function and Promoting Client Protein Folding
Cox, M. B., & Johnson, J. L. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7477-1_28 · Cited by 23
Self-citation
Metadata
- Authors
- Storer Samaniego, C., Suh, J. H., Chattopadhyay, A., Olivares, K., Guy, N., Sivils, J. C., Dey, P., Yumoto, F., Fletterick, R. J., Strom, A. M., Gustafsson, J.-Å., Webb, P., & Cox, M. B.
- Affiliations
- Houston Methodist (US)
- The University of Texas at El Paso (US)
- University of Houston (US)
- University of California, San Francisco (US)
- Corresponding author
- Cox, Marc B.
- ORCID
- Venue
- PLOS One
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-07-24
- Volume
- 10
- Issue
- 7
- Pages
- e0134015
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4514735
- OpenAlex
- W2141176467
- Cited by
- 13
- References
- 34
- Citations by year
- 2023: 2 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 3 · 2015: 1
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Kettering University Digital Commons (Kettering University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Prevention and Research Institute of Texas (RP110444-C2, RP110444-P2, RP110444-P3, RP110444-P1)
- National Institutes of Health
- National Institute of General Medical Sciences (SC1GM084863)
- National Institute on Minority Health and Health Disparities (G12MD007592)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- FKBP52, β-catenin, androgen receptor, prostate cancer, androgen receptor signaling, protein-protein interaction, ligand-binding domain, HSP90, transcriptional coactivation, androgen receptor antagonists
- MeSH terms
- Amino Acid Sequence, Binding Sites, HeLa Cells, Humans, Molecular Sequence Data, Protein Binding, Receptors, Androgen, Second Messenger Systems, Tacrolimus Binding Proteins, beta Catenin, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling. https://app.cochat.ai/papers/10.1371/journal.pone.0134015
- The paper
- Storer Samaniego, C., Suh, J. H., Chattopadhyay, A., Olivares, K., Guy, N., Sivils, J. C., Dey, P., Yumoto, F., Fletterick, R. J., Strom, A. M., Gustafsson, J.-Å., Webb, P., & Cox, M. B. (2015). The FKBP52 Cochaperone Acts in Synergy with β-Catenin to Potentiate Androgen Receptor Signaling. PLOS One. https://doi.org/10.1371/journal.pone.0134015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.